Fate Therapeutics (FATE) Assets Average (2013 - 2026)

Fate Therapeutics has reported Assets Average for 14 years, with the latest figure at $301.9 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average fell 28.06% year-over-year to $301.9 million; the trailing twelve-month figure through Mar 2026 stood at $301.9 million (down 28.06% YoY), and the FY2025 full-year result was $379.8 million, down 19.78% from the prior year.
• Assets Average for Q1 2026 stood at $301.9 million, down from $331.3 million in the prior quarter.
• The five-year high for Assets Average was $889.9 million in Q1 2022, with the low at $301.9 million in Q1 2026.
• Historically, Assets Average has averaged $556.2 million across 5 years, with a median of $538.1 million in 2024.
• Annual changes were most pronounced in 2022 — Assets Average climbed 6.68% — and 2025, when it slumped 30.13%.
• Fate Therapeutics' Assets Average stood at $727.5 million in 2022, then declined by 27.83% to $525.0 million in 2023, then slipped by 10.89% to $467.8 million in 2024, then declined by 29.18% to $331.3 million in 2025, then declined by 8.87% to $301.9 million in 2026.
• The last three Assets Average figures came in at $301.9 million (Q1 2026), $331.3 million (Q4 2025), and $357.7 million (Q3 2025), per Business Quant data.